Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

147 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-10-06

Study Completion Date

2022-01-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Coronavirus Disease 2019 (COVID-19) pandemic has claimed over 5 million lives globally. Fortunately, a substantial and growing number of SARS-CoV-2 vaccines with very high efficacy have been developed, manufactured, and rapidly approved. Novel mRNA vaccines such as the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) have reported a stunning \>94% efficacy against COVID-19. However, global access has not been equitable, with many low- and middle-income countries having no vaccine access or access under emergency use mainly to traditional inactivated SARS-CoV2-2 vaccines such as BBIBP-CorV (Sinopharm Beijing), CoronaVac (Sinovac) and BBV152 (Bharat Biotech). Emerging studies have shown that lower concentrations of neutralizing antibodies (Nab) are attained after CoronaVac than after an mRNA-based vaccine in healthy individuals. This difference seems to be more pronounced in immunocompromised patients who are at higher risk of severe COVID-19 and death from COVID-19. As such, several countries including the United States, Israel and Chile have recommended a third vaccine dose for high-risk populations. However, it is not currently known which is the best vaccine combination regarding immunogenicity, particularly in these vulnerable patients.

This observational study will explore the humoral and cellular response to a SARS-CoV-2 BNT162b2 vaccine booster in solid organ transplant patients who received two previous doses of the inactivated Coronavac or two doses of BNT162b2 vaccines.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of SARS-CoV-2 Vaccination in Liver Transplant Recipients

NCT05490342

SARS-CoV-2 Vaccination Liver Transplantation

COMPLETED

COVID19 Vaccine in SOT Adult Recipients

NCT05116748

COVID-19 Vaccine Adverse Reaction Vaccine Response Impaired +4 more

COMPLETED

EVALUATION OF DIFFERENT PROPHYLACTIC INTERVENTIONS TOWARD COVID-19 IN SOLID ORGAN TRANSPLANT PATIENTS

NCT05629923

COVID-19 Pandemic Transplant-Related Disorder

COMPLETED

Efficacy, Safety, and Immunogenicity of Vaccine Reimmunization With a Third Homologous Versus Heterologous Dose Against COVID-19 in Patients Undergoing Solid Organ Transplantation.

NCT05048940

Covid19

WITHDRAWN PHASE3

COVID Protection After Transplant-Immunosuppression Reduction

NCT05077254

Kidney Transplant Recipients Liver Transplant Recipients

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19 SARS-CoV-2 Infection Solid Organ Transplant Vaccine Response Impaired

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Three doses of BNT162b2 vaccine

Solid organ transplant patients who received three doses of BNT162b2

Three doses of SARS-CoV-2 BNT162b2 vaccine (observational)

Intervention Type BIOLOGICAL

Two doses of SARS-CoV-2 BNT162b2 mRNA vaccine, followed by a booster (3rd) dose of SARS-CoV-2 BNT162b2 mRNA vaccine.

Two doses of Coronavac and one of BNT162b2 vaccine

Solid organ transplant patients who received two doses of CoronaVac and one dose of BNT162b2

Two doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine (observational)

Intervention Type BIOLOGICAL

Two doses of CoronaVac SARS-CoV-2 inactivated vaccine, followed by a booster (3rd) dose of BNT162b2 mRNA vaccine.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Three doses of SARS-CoV-2 BNT162b2 vaccine (observational)

Two doses of SARS-CoV-2 BNT162b2 mRNA vaccine, followed by a booster (3rd) dose of SARS-CoV-2 BNT162b2 mRNA vaccine.

Intervention Type BIOLOGICAL

Two doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine (observational)

Two doses of CoronaVac SARS-CoV-2 inactivated vaccine, followed by a booster (3rd) dose of BNT162b2 mRNA vaccine.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Solid organ transplant patients in the last 10 years and currently under immunosuppressive therapy
* Vaccination with two doses of Coronavac vaccine or BNT162b2 vaccines, followed by a booster dose (3d dose) of BNT162b2 vaccine administered in the previous 8-12 weeks.

Exclusion Criteria

* Previous SARS-CoV-2 infection
* Booster vaccine (3rd dose) administered less than 8 weeks or more than 12 weeks before enrolment
* Intravenous immunoglobulin therapy 60 days before enrolment
* Previous SARS-CoV-2 vaccine different from CoronaVac or BNT162b2

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No